Turnstone Biologics Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TSBX research report →
Companyturnstonebio.com
Turnstone Biologics Corp. , a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas.
- CEO
- Sammy J. Farah
- IPO
- 2023
- Employees
- 14
- HQ
- LA Jolla, CA, US
Price Chart
Valuation
- Market Cap
- $8.21M
- P/E
- -0.27
- P/S
- 4.07
- P/B
- 0.56
- EV/EBITDA
- 0.29
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 35.08%
- Op Margin
- -1293.41%
- Net Margin
- -1494.95%
- ROE
- -136.68%
- ROIC
- -165.69%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-70,837,000 · -28.33%
- EPS
- $-3.07 · -12.45%
- Op Income
- $-72,494,000
- FCF YoY
- -0.39%
Performance & Tape
- 52W High
- $2.26
- 52W Low
- $0.29
- 50D MA
- $0.36
- 200D MA
- $0.41
- Beta
- 1.37
- Avg Volume
- 404.93K
Get TickerSpark's AI analysis on TSBX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 8, 25 | ORBIMED ADVISORS LLC | other | 3,099,265 |
| Aug 8, 25 | Versant Ventures V, LLC | other | 274,990 |
| Aug 8, 25 | Jerel Davis | other | 82,006 |
| Aug 8, 25 | Gupta Rishi | other | 3,099,265 |
| Jun 3, 24 | Rajangam Kanya | other | 12,770 |
| Jun 3, 24 | Gould Robert J | other | 12,770 |
| Jun 3, 24 | Gupta Rishi | other | 12,770 |
| Jun 3, 24 | Jerel Davis | other | 12,770 |
| Jun 3, 24 | Waddill William D. | other | 12,770 |
| Apr 15, 24 | Waddill William D. | other | 25,540 |
Our TSBX Coverage
We haven't published any research on TSBX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TSBX Report →